LYMPHOID NEOPLASIA Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma
نویسندگان
چکیده
1International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai; 2National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai; and 3School of Medicine and School of Pharmacy, Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
منابع مشابه
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.
Despite widespread use of the anti-CD20 monoclonal antibody (mAb), rituximab, in treating B-cell lymphomas, its efficacy remains variable and often modest. A better understanding of rituximab-mediated killing mechanisms is essential to develop more effective therapeutic agents. In this study, we modulated the binding property of rituximab by introducing several point mutations in its complement...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملIMMUNOBIOLOGY Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma Running head: ANTITUMOR ACTIVITY OF NEW RITUXIMAB VARIANTS
International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433, People’s Republic of China; National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai 201203, People’s Republic of China School of Medicine and School of Pharmacy, The Center for Antibody Medicine ...
متن کاملCancer Therapy: Preclinical rILYd4, a Human CD59 Inhibitor, Enhances Complement- Dependent Cytotoxicity of Ofatumumab against Rituximab- Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Purpose: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complementdependent cytotoxicity (CDC) than rituximab. Human CD59, a key membrane complement regulator that inhibits CDC, is highly expressed in B-cellmalignancies and its upregulation is an important determinant of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009